|
|
DRUG INTERACTIONS
ONTAK drug label information in our database does not contain a dedicated section on drug interactions. Please check subsections of WARNINGS AND PRECAUTIONS as well as other sources.
|
OVERDOSAGE
There is no clinical experience with accidental ONTAK overdosage and no known antidote. At a dose of 31 mcg/kg/day, the dose-limiting toxicities were moderate-to-severe nausea, vomiting, fever, chills and/or persistent asthenia. Doses greater than 31 mcg/kg/day have not been evaluated in humans. If overdose occurs, hepatic and renal function and overall fluid balance should be closely monitored.
|
CONTRAINDICATIONS
ONTAK is contraindicated for use in patients with a known hypersensitivity to denileukin diftitox or any of its components: diphtheria toxin, interleukin-2, or excipients.
|
REFERENCES
1.Nakase K, Kita K, Nasu K, Ueda T, Tanaka I, Shirakawa S and Tsudo M. Differential expression of interleukin-2 receptor ((alpha) and (beta) chain) in mature lymphoid neoplasms. Amer. J. Hematol. 1994; 46: 179-183.
Revised February 2002
Manufactured by:
Seragen, Incorporated
San Diego, CA 92121
US License No. 1258
Distributed by:
Ligand Pharmaceuticals Incorporated
San Diego, CA 92121
|
|
|
|
-- advertisement --
|
